Meta-analysis of statins in chronic kidney disease: Who benefits?

QJM: An International Journal of Medicine

Volumn 110, Issue 8, 2017, Pages 493-500

  Messow, C M ^a   Isles, C ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b DUMFRIES AND GALLOWAY ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; DRUG EFFICACY; ESTIMATED GLOMERULAR FILTRATION RATE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY TRANSPLANTATION; META ANALYSIS; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW; BLOOD; CAUSE OF DEATH; COMPLICATION; GLOMERULUS FILTRATION RATE; KIDNEY; MORTALITY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; GLOMERULAR FILTRATION RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; KIDNEY TRANSPLANTATION; LIPIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX;

EID: 85026835103     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcx040     Document Type: Article

References (39)

1. Qunibi WY. Dyslipidaemia in dialysis patients. Semin Dial 2015; 28:345-53
2. De Jager DJ, Grootendorst DC, Jager KJ, Van Dijk PC, Tomas LM, Ansell D, et al. Cardiovascular and non cardiovascular mortality among patients starting dialysis. Jama 2009; 302:1782-9
3. Holdaas H, Fellstrom B, Jardine AG, et al. on behalf of the Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of Fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361:2024-31
4. Wanner C, Krane V, Marz W, Olschewski M, Mann JFE, Ruf G. for the German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238-48
5. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, for the AURORA Study Group, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360:1393-407
6. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, on behalf of the SHARP investigators, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet 2011; 377:2181-92
7. Cholesterol Triallists Treatment Collaboration. Impact of renal function on the effects of LDL cholesterol lowering with statin based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet 2016; 4:829-39 (published online 28 July 2016)
8. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GFM. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157:263-75
9. Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM. Lipid-lowering therapy in persons with chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med 2012; 157:251-62
10. Su X, Zhang L, Lv J, Wang J, Hou W, Xie X, et al. Effects of statins on kidney disease outcomes: a systematic review and meta-analysis. Am J Kidney Dis 2016; 67:881-92
11. Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, et al. Outcome of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J 2013; 34:1807-17
12. Green D, Ritchie JP, Kalra PA. Meta-analysis of lipid lowering therapy in maintenance dialysis patients. Nephron Clin Pract 2013; 124:209-17
13. Major RW, Cheung CK, Gray LJ, Brunskill NJ. Statins and Cardiovascular Prevention in CKD: a meta-analysis. Clin J Am Soc Nephrol 2015; 10:732-9
14. Yan Y-L, Qiu B, Wang J, Deng S-B, Wu L, Jing X-D, et al. High intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis. BMJ Open 2015; 5:e006886
15. Tonelli M, Wanner C. for the Kidney Disease Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in a chronic kidney disease: synopsis of the kidney disease: improving a global outcomes 2013 clinical practice guideline. Ann Intern Med 2014; 160:182-89
16. Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013; Issue Art. No.: CD004816
17. Kendrick J, Shlipak MG, Targher G, Cook T, Lindenfeld J, Chonchol M. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a posthoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am J Kidney Dis 2010; 55:42-9
18. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, CARDS Investigators, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: An analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009; 54:810-9
19. Ridker PM, MacFadyen J, Cressman M, Glynn RJ. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol 2010; 55:1266-73
20. Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y. MEGA Study Group: Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis 2009; 206:512-7
21. Chonchol M, Cook T, Kjekshus J, Pedersen TR, Lindenfeld J. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis 2007; 49:373-8
22. Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo controlled trial. Lancet 2002; 360:7-22
23. Lemos PA, Serruys PW, de Feyter P, Mercado N, Goedhart D, Saia F, et al. Long term Fluvastatin reduces the hazardous effect of renal impairment on four year atherosclerotic outcomes (a LIPS substudy). Am J Cardiol 2005; 95:445-51
24. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623-30
25. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004; 110:1557-63
26. Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP. on behalf of the ALLIANCE Investigators. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis 2009; 53:741-50
27. Study of the effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Study Group. Intensive lowering of LDL cholesterol with 80mg versus 20mg simvastatin daily in 12064 survivors of myocardial infarction: a double blind randomized trial. Lancet 2010; 376:1658-69
28. Shepherd J, Kastelein JJP, Bittner V, Deedwania P, Breazna V, Dobson S, for the TNT Investigators, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The TNT (Treating tońew Targets) Study. J Am Coll Cardiol 2008; 51:1448-54
29. Landray M, Baigent C, Leaper C, Adu D, Altman P, Armitage A, et al. The second UK Heart and Renal Protection (UK-HARP-II) study: a randomised controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with chronic. Kidney Dis Am J Kidney Disease 2006; 47:385-95
30. Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, on behalf of the Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators, et al. Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005; 5:2929-36
31. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17:2815-34
32. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2016. https://www.R-project.org/
33. Del Re AC, Hoyt WT. MAd: Meta-analysis with mean differences. R package version 0.8-2, 2014. http://cran.r-project.org/ web/packages/MAd
34. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw 2010; 36:1-48. http://www.jstat soft.org/v36/i03/
35. JBS3: Joint British Societies' consensus recommendations for the prevention of cardiovascular disease. Heart 2014; 100(Supp 2):1-67
36. NICE CG181. Cardiovascular disease: risk assessment and reduction, including lipid modification, July 2014
37. Stevens PE, O'Donoghue DJ, de Lusignan S, Van Vlymen J, Klebe B, Middleton R, et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 2007; 72:92-99
38. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW. for theWest of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl JMed 1995; 333:1301-7
39. Sattar N, Preiss D, Murray H, Welsh P, Buckley B, de Crean AJM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375:735-42